S2 Ep12: Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management

PER Spectives

This podcast features engaging commentary from experts in the clinical management of generalized myasthenia gravis— James Howard, Jr, MD and Nicholas Sylvestri, MD. These experts discuss the burden of disease associated with the disorder, its pathogenesis in terms of the complement system, and the clinical considerations for incorporating appropriate targeted therapy to improve health-related outcomes. Emphasis is placed on the interpretation of recently published or presented data regarding anti-complement therapies. The exerts provide key take-home points and pearls for practice.
Nicholas J. Silvestri, MD
Professor of Neurology
University at Buffalo Jacobs School of Medicine and Biomedical Sciences
Buffalo, NY
Disclosures: Consultant: Argenx, UCB, Immunovant, Alexion, Janssen.
James F. Howard Jr, MD
Professor of Neurology
The University of North Carolina at Chapel Hill
Chapel Hill, NC
Disclosures: Honorarium: Alexion Pharmaceuticals. Argenx, Biologix Pharma. Research support to institution: Alexion Pharmaceuticals Argenx, Biologix Pharma, Millennium Pharmaceuticals.